Aeterna Zentaris Inc represents values of innovation, integrity, and a commitment to improving patient outcomes. The company's corporate philosophy revolves around developing novel therapeutics for unmet medical needs. Aeterna Zentaris Inc aims to provide value for shareholders by advancing its pipeline of pharmaceutical products and maximizing commercial opportunities. With a focus on research and development, the company strives to deliver high-quality treatments that address significant medical challenges. By embracing cutting-edge science and partnering with key stakeholders, Aeterna Zentaris Inc aims to make a positive impact on the healthcare industry and the lives of patients worldwide.

Aeterna Zentaris Inc is primarily present in the United States and Canada.

Some significant milestones achieved by Aeterna Zentaris Inc. include the acquisition of rights to develop and commercialize Macrilen™, a diagnostic agent for adult growth hormone deficiency, in the United States and Canada. The company also received FDA approval for Macrilen™, which marked an important regulatory milestone. Additionally, Aeterna Zentaris Inc. successfully completed a Phase 3 clinical study for Zoptrex™ (zoptarelin doxorubicin), a potential treatment for endometrial cancer, demonstrating positive results. These achievements reflect the company's commitment to advancing innovative therapies and expanding its product portfolio.

Aeterna Zentaris Inc., a biopharmaceutical company, was founded in 1990 and is headquartered in Canada. With a focus on developing innovative treatments in oncology, endocrinology, and other therapeutic areas, Aeterna Zentaris aims to improve the lives of patients worldwide. Through comprehensive research and development efforts, the company has successfully advanced several drug candidates, addressing unmet medical needs. Aeterna Zentaris Inc. has built a strong portfolio of potential treatment options, including Macrilen™ for growth hormone deficiency in adults. Continually striving for medical advancements, Aeterna Zentaris Inc. remains dedicated to improving patient outcomes and addressing critical healthcare challenges.

The main competitors of Aeterna Zentaris Inc in the market include pharmaceutical companies like Novartis, Pfizer, and Bristol-Myers Squibb.

Aeterna Zentaris Inc is primarily active in the pharmaceutical industry.

Aeterna Zentaris Inc is a biopharmaceutical company focused on developing and commercializing innovative therapies for various diseases. The company's business model revolves around conducting research and development activities to discover and develop novel treatments. Aeterna Zentaris Inc aims to address unmet medical needs and improve patients' lives through the development of innovative drugs. With a strong focus on oncology and endocrinology, the company combines scientific expertise and strategic partnerships to advance its pipeline of promising drug candidates. Aeterna Zentaris Inc strives to bring effective and life-changing therapies to market, ensuring better healthcare outcomes for patients worldwide.

Aeterna Zentaris의 P/E 비율은 -0.35입니다.

Aeterna Zentaris의 P/S 비율은 1.03입니다.

Aeterna Zentaris에 대한 AlleAktien 품질 점수는 3/10입니다.

예상되는 Aeterna Zentaris 매출은 4.39 백만 USD입니다.

예상되는 Aeterna Zentaris 이익은 -12.72 백만 USD입니다.

Aeterna Zentaris Inc. is a biopharmaceutical company based in Canada that focuses on the development and commercialization of drugs for the treatment of cancer and other serious diseases. The company operates in three core business areas: oncology, endocrinology, and hematology. In the oncology field, Aeterna Zentaris has several products in the pipeline for the treatment of gastric cancer and prognostically unfavorable breast cancer. The company also has a diagnostic test kit called Macrilen® for stimulating growth hormone in adults to diagnose growth hormone deficiency. In the endocrinology field, Aeterna Zentaris is a leader in the development of peptide-based drugs for the treatment of hormonal disorders. The company has two main products in the pipeline: Macimorelin, a diagnostic test kit for stimulating growth hormone in children, and Zoptrex, a drug for the treatment of endometriosis. In the hematology field, Aeterna Zentaris focuses on developing therapies for the treatment of serious blood disorders such as leukemia and non-Hodgkin lymphoma. The company has several products in the pipeline, including AEZS-142, a drug currently being studied in a phase 3 clinical trial for the treatment of lymphomas. Aeterna Zentaris has a clinical development platform based on the identification of peptide-based drugs and other potential compounds. The company utilizes this platform to develop innovative therapies for the treatment of cancer and other serious diseases. The business model of Aeterna Zentaris is based on leveraging different areas such as oncology, endocrinology, and hematology to develop and market innovative peptide-based drugs for the treatment of cancer and blood disorders. The capture of powerful and meaningful data through targeted clinical studies enables the company to advance its pipeline of drug developments and offer potential customers a wide range of products in various therapeutic areas. Overall, Aeterna Zentaris is an emerging biopharmaceutical company with a strong focus on innovative treatment options for serious diseases. The company is committed to advancing the exploration of peptide therapeutics in disease areas such as endocrinology, oncology, and hematology through the further development of its portfolio of clinical development programs.

Aeterna Zentaris은(는) 연간 번의 배당을 통해 0 USD의 배당금을 지급합니다.

Aeterna Zentaris의 현재 배당금은 계산할 수 없거나, 회사가 배당금을 지급하지 않습니다.

Aeterna Zentaris의 ISIN은 CA0079754028입니다.

Aeterna Zentaris의 WKN은 A1439Z입니다.

Aeterna Zentaris의 티커는 AEZS.TO입니다.

지난 12개월 동안 Aeterna Zentaris은(는) 의 배당금을 지급했습니다. 이는 약 의 배당 수익률에 해당합니다. 향후 12개월 동안 Aeterna Zentaris은(는) 0 USD의 배당금을 지급할 것으로 예상됩니다.

Aeterna Zentaris의 현재 배당 수익률은 입니다.

Aeterna Zentaris은 분기별로 배당금을 지급합니다. 이는 월에 배당됩니다.

Aeterna Zentaris은(는) 지난 0년 동안 매년 배당금을 지급했습니다.

향후 12개월 동안 0 USD의 배당금이 예상됩니다. 이는 배당수익률 0 %에 해당합니다.

Aeterna Zentaris은 '건강' 섹터에 속합니다.

Aeterna Zentaris의 마지막 배당금을 0 USD만큼 받기 위해선 의 Ex-Tag 전에 주식을 보유하고 있어야 했습니다.

마지막 배당금 지급일은 입니다.

2023년에 Aeterna Zentaris는 0 USD를 배당금으로 지급했습니다.

Aeterna Zentaris의 배당금은 USD에 지급됩니다.